Advaxis Stock Insider Trading

Healthcare > Biotechnology

Buy ADXS

*Your capital is at risk

$0.604

+0 (+0%)

At Close: May 01, 2026

Advaxis Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 228.25M and sold 10.59M ADXS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	228.25M shares
● Sell	10.59M shares
94% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 07, 2024 Buy	Warrants M-Exempt	Israel Biotech Fund I, L.p.	Director	8 437 500 Value: $3.38M
Feb 07, 2024 Buy	Warrants M-Exempt	Israel Biotech Fund I, L.p.	Director	8 437 500 Value: $3.38M
Feb 07, 2024 Buy	Common Stock, par value $0.001 per share M-Exempt	Israel Biotech Fund I, L.p.	Director	1 926 221 Value: $770.5K
Feb 07, 2024 Buy	Convertible Promissory Note M-Exempt	Israel Biotech Fund I, L.p.	Director	3 887 438 Value: $1.55M
Feb 07, 2024 Buy	Warrants M-Exempt	Israel Biotech Fund I, L.p.	Director	8 062 500 Value: $3.23M
Feb 07, 2024 Buy	Convertible Promissory Note M-Exempt	Israel Biotech Fund I, L.p.	Director	1 926 221 Value: $770.5K
Feb 07, 2024 Buy	Convertible Promissory Note M-Exempt	Israel Biotech Fund I, L.p.	Director	1 295 813 Value: $518.3K
Feb 07, 2024 Buy	Common Stock, par value $0.001 per share M-Exempt	Israel Biotech Fund I, L.p.	Director	3 887 438 Value: $1.55M
Feb 07, 2024 Buy	Common Stock, par value $0.001 per share M-Exempt	Israel Biotech Fund I, L.p.	Director	4 237 687 Value: $1.70M
Feb 07, 2024 Buy	Convertible Promissory Note M-Exempt	Israel Biotech Fund I, L.p.	Director	4 237 687 Value: $1.70M
Feb 07, 2024 Buy	Common Stock, par value $0.001 per share M-Exempt	Israel Biotech Fund I, L.p.	Director	1 295 813 Value: $518.3K
Feb 07, 2024 Sell	Common Stock, par value $0.001 per share F-InKind	Israel Biotech Fund I, L.p.	Director	2 707 581 Value: $3.37M
Feb 07, 2024 Buy	Common Stock, par value $0.001 per share M-Exempt	Israel Biotech Fund I, L.p.	Director	8 437 500 Value: $3.38M
Feb 07, 2024 Sell	Common Stock, par value $0.001 per share F-InKind	Israel Biotech Fund I, L.p.	Director	2 586 905 Value: $3.22M
Feb 07, 2024 Buy	Common Stock, par value $0.001 per share M-Exempt	Israel Biotech Fund I, L.p.	Director	8 062 500 Value: $3.23M
Nov 17, 2023 Buy	Rights P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	10 312 500 Value: $4.13M
Nov 17, 2023 Buy	Rights P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	4 687 500 Value: $1.88M
Nov 17, 2023 Buy	Rights P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	3 150 000 Value: $1.26M
Nov 17, 2023 Buy	Rights P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	3 150 000 Value: $1.26M
Nov 17, 2023 Buy	Warrants P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	5 625 000 Value: $2.25M
Nov 17, 2023 Buy	Warrants P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	6 187 500 Value: $2.48M
Nov 17, 2023 Buy	Warrants P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	6 187 500 Value: $2.48M
Nov 17, 2023 Buy	Warrants P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	2 812 500 Value: $1.13M
Nov 17, 2023 Buy	Convertible Promissory Note P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	0 Value: $0
Nov 17, 2023 Buy	Convertible Promissory Note P-Purchase	Israel Biotech Fund I, L.p. 10 Percent Owner	10% Owner	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ADVAXIS

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by